Back to Authors

Ayad, Ahmad A.

Mayo Clinic

Mayo Clinic

Citations 2

Quadriplegia in a Child With Spinal Arteriovenous Metameric Syndrome
Mansour, Moustafa , ali, hassan, Ayad, Ahmad A., Mansour, Moustafa A, Mansour, Moustafa A

Neurology | August 18, 2023 | Volume: 101 | Issue: 15 | Pages: 672-673

10.1212/wnl.0000000000207539 Get It

P21 Overexpression Promotes Cell Death and Induces Senescence in Human Glioblastoma
Mansour, Moustafa , Ayad, Ahmad A., Warrington, Arthur E. , Burns, Terry C. , Mansour, Moustafa A, Rahman, Masum , Burns, Terry C , Mansour, Moustafa A

Cancers | February 17, 2023 | Volume: 15 | Issue: 4 | Pages: 1279

10.3390/cancers15041279 Get It

High-grade gliomas are the most common and aggressive adult primary brain tumors with a median survival of only 12–15 months. Current standard therapy consists of maximal safe surgical resection followed by DNA-damaging agents, such as irradiation and chemotherapy that can delay but not prevent inevitable recurrence. Some have interpreted glioma recurrence as evidence of glioma stem cells which persist in a relatively quiescent state after irradiation and chemotherapy, before the ultimate cell cycle re-entry and glioma recurrence. Conversely, latent cancer cells with a therapy-induced senescent phenotype have been shown to escape senescence, giving rise to more aggressive stem-like tumor cells than those present in the original tumor. Therefore, approaches are needed to either eliminate or keep these glioma initiating cells in a senescent state for a longer time to prolong survival. In our current study, we demonstrate that the radiation-induced cell cycle inhibitor P21 can provide a powerful route to induce cell death in short-term explants of PDXs derived from three molecularly diverse human gliomas. Additionally, cells not killed by P21 overexpression were maintained in a stable senescent state for longer than control cells. Collectively, these data suggest that P21 activation may provide an attractive therapeutic target to improve therapeutic outcomes.